Launch of ColonCADT online CTC platform
25 Juni 2009 - 4:05PM
UK Regulatory
TIDMMDST
RNS Number : 5250U
Medicsight Plc
25 June 2009
+----------------------------------+-------------------------------------+
| Press Release | 25 June 2009 |
+----------------------------------+-------------------------------------+
Medicsight PLC
("Medicsight" or "the Company")
Medicsight launches ColonCAD(TM) online CTC platform
Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, is pleased to announce the launch of its
online product, MedicRead(TM) 3.0 Colon. This online offering makes the benefits
of Medicsight's ColonCAD software truly accessible to all radiologists for the
first time.
MedicRead(TM) 3.0 Colon is the Company's own advanced visualisation platform,
integrated with Medicsight's ColonCAD(TM) software to help radiologists read
computer tomography (CT) scans for the detection of colonic polyps, which may be
the precursors of colon cancer. The online version is downloadable from
www.medicsight.com making CAD accessible to the global radiology
community.MedicRead(TM) 3.0 Colon online will be sold as a total solution with
either a single list price or available on a monthly installment basis over 12
months.
Allan Rowley, Chief Executive of Medicsight commented, "The launch of our online
MedicRead 3.0 Colon platform provides the Company with an additional revenue
stream. It is the only visualisation workstation that can be accessed and
downloaded online enabling the international radiology community to experience
and take advantage of the clinical benefits of ColonCAD."
Access to Medicsight's ColonCAD(TM) software is currently available through the
Company's
partners' advanced 3D visualisation platforms. As part of the
Company's ongoing commitment to radiologists and to improving the early
detection of colorectal cancer, Medicsight has developed
MedicRead 3.0 Colon.
This is a competitively priced, stand-alone, CTC visualisation
workstation,
incorporating the latest version of ColonCAD 4.0 as well as
Medicsight's MedicServer(TM)
technology. MedicRead 3.0 Colon offers a
valuable centralised pre-processing platform that accepts DICOM CT image data
from either the CT console or any PACS system.
The new online application is being showcased on the Medicsight booth (number
13) at ESGAR 2009, which is taking place this week in Valencia. Additionally, a
30 day free trial version of the
software can be downloaded from the
Medicsight new website www.medicsight.com allowing
radiologists to experience
the benefits of ColonCAD first hand.
MedicRead 3.0 Colon is not currently available for sale in the United States.
- ENDS -
For further information:
+------------------------------------------------+-------------------------+
| Medicsight PLC | www.medicsight.com |
+------------------------------------------------+-------------------------+
| Allan Rowley | +44 (0)20 7605 7950 |
+------------------------------------------------+-------------------------+
| Daniel Stewart & Company PLC | |
+------------------------------------------------+-------------------------+
| Simon Leathers / Charlotte Stranner | +44 (0) 20 7776 6550 |
+------------------------------------------------+-------------------------+
| | |
+------------------------------------------------+-------------------------+
| Media enquiries: | |
| | |
+------------------------------------------------+-------------------------+
| Abchurch Communications | +44 (0) 20 7398 7700 |
+------------------------------------------------+-------------------------+
| | |
+------------------------------------------------+-------------------------+
| Heather Salmond / Stephanie Cuthbert / Simone | +44 (0) 20 7398 7718 |
| Alves | |
+------------------------------------------------+-------------------------+
| stephanie.cuthbert@abchurch-group.com | www.abchurch-group.com |
+------------------------------------------------+-------------------------+
Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung,
helping radiologists to identify, measure and analyse potential disease and
early indicators of disease. Medicsight's CAD software has been validated using
one of the world's largest and most population diverse databases of verified
patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software
products are seamlessly integrated with the advanced 3D visualisation
workstations of several industry-leading imaging equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 2000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This can
be critical for diagnosis and the management of patient outcomes as early
detection of disease greatly increases the probability of successful treatment
and a positive therapeutic outcome. In addition to supporting individual
radiologists CAD also has the potential to help standardise CT interpretation
across both individuals and institutions thereby supporting population based
screening programmes.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm
to analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.
Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEFFLISUSESM
Medicsight (LSE:MDST)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Medicsight (LSE:MDST)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
Echtzeit-Nachrichten über Medicsight (Londoner Börse): 0 Nachrichtenartikel
Weitere Medicsight News-Artikel